Uranium Energy Corp

Thesis

UEC owns the largest licensed uranium production platform in the US (~12M lbs/yr) and just achieved a genuine operational inflection — first production at Burke Hollow in April 2026, the first new US ISR mine in over a decade — but at $9.73 the market pays ~$4.8B for $20.2M of TTM revenue and a ~130k lbs/yr annualized production run-rate. Our base case (4M lbs/yr by FY2031 at $80/lb realized, a 6x mature EV/Sales exit) supports only ~$3.83/share in year 5, a −17%/yr IRR from today's price. The stock only works from here if UEC utilizes nearly all of its licensed capacity within 5 years AND the market sustains today's scarcity premium — a joint bet we cannot underwrite; this publishes as a watchlist note, not a buy.

Why Now

The operational inflection is real and filing-verifiable. On April 8, 2026, UEC commenced production at Burke Hollow in South Texas (8-K filed 2026-04-08) — the first new US in-situ recovery uranium mine in more than a decade, with a 2,500 gallon-per-minute satellite ion-exchange plant commissioned and Phase 1A wellfield development underway. At Christensen Ranch in Wyoming, three new header houses in Wellfield 11 entered production late in fiscal Q3 2026, with five more under construction (Q3 FY2026 results, released with the 10-Q filed 2026-06-09). Cumulative production since the August 2024 restart reached 276,516 lbs of U3O8 at a cumulative total cost of $39.30/lb, and the company holds 1.456M lbs of strategic inventory valued at ~$127M at market.

The balance sheet is the strongest in UEC's history: $488.1M in cash, zero debt, and ~$794M of total liquid assets (10-Q for the quarter ended 2026-04-30, filed 2026-06-09), after an opportunistic ~$300M equity raise in October 2025 (424B5s filed 2025-10-03/06) executed near the stock's highs — cash jumped from $148.9M at 7/31/25 to $454.7M at 10/31/25 (10-Q filed 2025-12-10). The macro backdrop supports the theme: spot U3O8 sits near $86/lb and the TradeTech long-term price hit $93/lb on March 31, 2026, its highest level in over 18 years, while US policy continues to favor domestic supply following the Russian uranium import ban.

Here is the honest problem: the revenue line does not yet reflect any of this, and the price already reflects all of it. TTM revenue (May 2025–April 2026) is $20.2M — a single Q2 FY2026 inventory sale (10-Q filed 2026-03-10); the other three quarters were zero, and fiscal Q3 2026 production was just 32,195 lbs at a total cost of $54.61/lb. UEC's entire FY2025 revenue of $66.8M (10-K filed 2025-09-24) also came from inventory sales, not sustained production. The inflection is a reason to start the clock on the ramp — not, at ~238x TTM sales, a reason to own the stock today.

Business Quality

UEC's moat is regulatory and locational, not operational. It controls roughly 12M lbs/yr of licensed production capacity across two hub-and-spoke ISR platforms (Hobson in South Texas, Irigaray in Wyoming) plus the Sweetwater plant acquired from Rio Tinto — the largest licensed uranium capacity in the United States, in the only western jurisdiction with an explicit policy tailwind (the Russian import ban and US fuel-cycle re-shoring). Licenses of this kind take a decade-plus to replicate, and Burke Hollow's April 2026 startup proves the company can permit and commission new capacity. The Roughrider project in Saskatchewan (pre-feasibility drilling 80% complete as of Q3 FY2026) adds a high-grade conventional option beyond the 5-year window.

Unit economics are unproven at scale, and this is the crux. Cumulative production since the 2024 restart is 276,516 lbs — about 2% of licensed capacity per year — and the most recent quarter's total cost of $54.61/lb ($46.69 cash) ran well above the cumulative $39.30/lb, moving the wrong way during ramp-up. US ISR restarts have a long industry history of underdelivering nameplate; UEC itself produced from these Texas assets in 2011–2015 at rates far below licenses. Until the company demonstrates ~1M+ lbs/yr at sub-$40 cash costs, "12M lbs licensed" is an option, not an earnings stream. The deliberately 100% unhedged, no-term-contract strategy maximizes torque to uranium prices in both directions and means there is no contracted backlog to underwrite.

Capital allocation is a mixed record executed with genuine discipline on the debt side: zero debt ever, and equity raised opportunistically at high prices (the October 2025 raise added ~$306M for ~29M shares, ~$10.50/share net). But the share count compounds relentlessly — 454.0M at 7/31/25 to 494.9M by 6/8/26, roughly 9% dilution in under a year — and the strategy is serially acquisitive (UEX, Rio Tinto's Sweetwater complex, Roughrider). Shareholders are funding a land-and-license aggregation; whether it converts to per-share value depends entirely on the ramp and the uranium price.

Financial Base

Reference figures as of 2026-07-23: trailing-twelve-month revenue of $20M, 494.9M diluted shares, net debt of $-488M, and a share price of $9.73. Sources:

• 10-Q for fiscal Q3 2026 (period ended 2026-04-30), filed 2026-06-09, acc. 0001437749-26-019889 — Q3 revenue $0; FY2026 YTD revenue $20.2M; cash & equivalents $488.053M; no debt (total liabilities $116.6M are chiefly deferred tax and asset-retirement obligations); 493,317,899 shares outstanding at 4/30/26 and 494,872,366 at the 6/8/26 cover date
• 10-Q for fiscal Q2 2026 (period ended 2026-01-31), filed 2026-03-10 — Q2 revenue $20.2M, the only non-zero revenue quarter in the TTM window (an inventory sale)
• 10-Q for fiscal Q1 2026 (period ended 2025-10-31), filed 2025-12-10 — Q1 revenue $0; cash $454.7M after the October 2025 equity offering (424B5 prospectus supplements filed 2025-10-03 and 2025-10-06)
• 10-K for FY2025 (period ended 2025-07-31), filed 2025-09-24 — FY2025 revenue $66.837M, all recognized by fiscal Q2 (Q4 FY2025 revenue $0), sourced from inventory sales; establishes Q4-FY25 contribution of $0 to the TTM sum
• 8-K filed 2026-04-08 — commencement of production at Burke Hollow, first new US ISR uranium mine in over a decade
• Q3 FY2026 results release, 2026-06-09 (with 8-K acc. 0001437749-26-020021) — 32,195 lbs produced in Q3 at $54.61/lb total cost; 276,516 lbs cumulative since the FY2025 restart at $39.30/lb; 1.456M lbs inventory (~$127M at market); ~$794M liquid assets; ~12M lbs/yr licensed capacity
• Share price $9.73 at 2026-07-23 close (Robinhood/TradingView quote pages; intraday range $9.41–$9.83; 52-week range $7.80–$20.34; market cap ~$4.95B)

Scenario Valuation

Five-year scenario ranges under the published methodology — the tables below are computed from these exact parameters at publication and sealed with this text. What each scenario assumes:

• Loss (10%): Uranium falls below $60/lb for an extended period (SMR-demand disappointment plus Kazakh/restart supply), the ISR ramp stalls technically as US restarts have repeatedly done, and the unhedged, no-backlog model forces years of ATM dilution near the lows; ~$2.00 approximates today's liquid-asset backing (~$794M ≈ $1.60/share) with modest residual option value.
• Bear (30%): Chronic ramp disappointment — the pattern of every US ISR restart cycle: ~2M lbs/yr by FY2031 at ~$70/lb realized (~$148M revenue) with continued ATM funding; 5x EV/Sales matches a sub-scale, high-cost single-commodity producer (below Kazatomprom's ~5x with far better economics). Note the 49% CAGR is an artifact of the near-zero $20.2M base, not a growth claim.
• Base (45%): The ramp broadly works: ~4M lbs/yr by FY2031 (Christensen Ranch ~2M + Burke Hollow/Texas ~1.5M + early Sweetwater) at ~$80/lb realized ≈ $322M revenue; 6x EV/Sales sits between Kazatomprom (~5x) and Cameco's historical mid-cycle (6–8x) for a mid-cost producer with remaining growth optionality. Yields ~$3.83/share in year 5 — a −17%/yr IRR from $9.73.
• Bull (15%): Everything goes right: ~7.5M lbs/yr by FY2031 at ~$95/lb realized (term price holds near the March 2026 $93/lb 18-year high, plus a US-origin premium) ≈ $700M revenue; 8x EV/Sales reflects a premier western producer with Roughrider still ahead — Cameco-like status without froth. Even so, year-5 value is ~$10.56/share, only ~2%/yr above today's price.

Published range (present value): $1.10 – $6.56 · probability-weighted expected value $2.58 against $9.73 at drafting (0.27×) · base-case IRR −17.0%/yr. Gates: base IRR ≥ 15% and EV ≥ 1.3× — both passed at publication. Ranges are graded at the 1-year checkpoint and the 5-year horizon. This is a range, not a target.

Sensitivity — present value across growth × exit multiple

The shaded cell is the one today's price of $9.73 most closely implies. Find your own cell — we show our work rather than assert a number.

Kill Conditions

1. 1. Ramp failure: trailing-12-month drummed U3O8 production below 750,000 lbs in the FY2027 10-K (fiscal year ending 2027-07-31), or any two consecutive quarters after January 2027 with production below 100,000 lbs — versus the multi-million-lb/yr trajectory the valuation requires (checkable in each 10-Q/10-K operational summary).
2. 2. Cost structure: cash cost per pound above $50 for two consecutive quarters once quarterly production exceeds 250,000 lbs — meaning scale is not delivering the sub-$40 economics the base case assumes (reported in quarterly results releases).
3. 3. Dilution treadmill: shares outstanding (10-Q/10-K cover page) grow more than 8% over any trailing 12 months without an accompanying acquisition of producing assets — indicating operations are not self-funding and the ATM is financing standstill.
4. 4. Price thesis breaks: U3O8 spot below $60/lb for two consecutive quarters (TradeTech/UxC monthly indicators) — below the incentive price for new western supply and roughly UEC's demonstrated all-in cost plus capital burden, which guts the unhedged model.

Risk Register

• Valuation premium — severe: ~238x TTM revenue and ~$4.8B market cap versus a ~$322M base-case FY2031 revenue; the market has pre-paid for near-full execution plus a permanent scarcity multiple.
• Ramp execution — high: 276,516 lbs cumulative in ~7 quarters (~2%/yr of licensed capacity); Q3 FY2026 production of 32,195 lbs annualizes to ~130k lbs; US ISR restarts have chronically missed nameplate for two decades.
• Uranium price exposure — high: deliberately 100% unhedged with no term contracts or backlog; revenue timing is opportunistic (three of the last four quarters were $0), so both earnings and sentiment swing with spot.
• Dilution — high: 454.0M to 494.9M shares in ~10 months (~9%); the FY2025 pace was higher still; growth capex for Burke Hollow, Sweetwater, and Roughrider will keep the ATM active.
• Cost inflation — medium: Q3 FY2026 total cost of $54.61/lb rose above the $39.30/lb cumulative figure during ramp-up; margins at $80/lb are thinner than the story implies if this persists.
• Flow/momentum volatility — medium: 52-week range of $7.80–$20.34 with no fundamental change of that magnitude; the stock trades as a thematic vehicle, so drawdowns can be violent and disconnected from operations.

Theme Position

Revenue exposure to the nuclear-fuel-cycle theme is 100%: every dollar of UEC revenue is U3O8 concentrate sales into the front end of the fuel cycle, and the asset base (ISR platforms, Sweetwater, Roughrider, physical inventory) is pure uranium.

Alternatives considered. Cameco (CCJ) is the mature way to own the theme — ~$3B revenue, a real contract book, and the Westinghouse stake — but it is the consensus holding and also trades at a demanding multiple; it would score better on quality but was outside this note's US-production-capacity angle. Centrus Energy (LEU) has what UEC lacks — genuine revenue, a contracted backlog, and the only US HALEU line — but it is an enrichment (not mining) story with single-facility concentration and Russian LEU supply entanglement; it deserves its own thesis rather than serving as a substitute here. Sprott Physical Uranium Trust (U.UN) arguably dominates UEC for expressing a uranium-price bull view: at roughly NAV you get the commodity with zero execution risk and zero dilution, whereas UEC at ~$4.8B embeds both commodity beta and a large prepaid execution bet. Kazatomprom offers the world's cheapest pounds at ~5x sales but carries Kazakh custody and routing risk that directly contradicts the western-security-of-supply premise of this theme. The honest conclusion: UEC is the purest listed claim on future US uranium production capacity, and that is exactly what its price already pays for.

Benchmark

Beating means total return above QQQ's total return over the full 5-year window from publication; our base case of −17%/yr implies UEC loses to QQQ decisively unless the market permanently sustains today's ~15x+ forward-scarcity multiple. Success means beating QQQ's total window return from publication; the scoreboard grades this thesis against that bar, live, whether we like the answer or not.